CAMBRIDGE, Mass.--(

马萨诸塞州剑桥--(

BUSINESS WIRE

商业热线

)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has closed on a $600 million senior secured revolving credit facility with a bank syndicate.

)--罕见疾病精准遗传医学的领导者Sarepta Therapeutics，Inc.（纳斯达克股票代码：SRPT）今天宣布，已与一家银行辛迪加达成6亿美元的高级担保循环信贷协议。

'

'

Sarepta's financial strength and the positive outlook for our business provide us with the flexibility to use non-dilutive financing by establishing a revolving credit facility. It supplements our strong balance sheet and allows for contingent liquidity as we execute our strategic plan to achieve our Sarepta 2030 objectives.

Sarepta的财务实力和对我们业务的积极展望为我们提供了通过建立循环信贷机制来使用非稀释性融资的灵活性。它补充了我们强大的资产负债表，并在我们执行战略计划以实现2030年Sarepta目标时考虑到了或有流动性。

Access to this instrument is a testament to our robust future cash and EBITDA growth trajectory and we were very pleased with the strong backing from the lenders during this process, which resulted in oversubscribed demand,' stated Ian Estepan, executive vice president, chief financial officer, Sarepta Therapeutics..

Sarepta Therapeutics执行副总裁兼首席财务官伊恩·埃斯特潘（IanEstepan）表示，获得这一工具证明了我们未来现金和息税折旧摊销前利润的强劲增长轨迹，我们非常高兴在此过程中得到了贷款人的大力支持，这导致了超额认购需求。。

JPMorgan Chase Bank, N.A. serves as Administrative Agent and acted as Lead Arranger and Joint Bookrunner. The syndicate also includes Barclays Bank PLC, Citizens Bank, N.A., Goldman Sachs USA, Morgan Stanley Senior Funding, Inc., Royal Bank of Canada, Fifth Third Bank, National Association, UBS AG, Stamford Branch and Bank of America.

摩根大通银行（JPMorgan Chase Bank，N.A.）担任行政代理人，并担任牵头安排行和联合账簿管理人。该财团还包括巴克莱银行（Barclays Bank PLC）、公民银行（Citizens Bank，N.A.）、美国高盛（Goldman Sachs USA）、摩根士丹利高级融资公司（Morgan Stanley Senior Funding，Inc.）、加拿大皇家银行（Royal Bank of Canada）、第五第三银行（Fifth Third Bank）、国家协会（National Association）、瑞士联合银行（UBS AG。

Additional information about the credit facility is contained in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 14, 2025..

有关信贷安排的其他信息，请参见公司于2025年2月14日向美国证券交易委员会提交的表格8-K的最新报告。。

About Sarepta Therapeutics

关于Sarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.

萨雷塔正在执行一项紧急任务：为罕见疾病设计精确的基因医学，这些疾病会破坏生命并缩短未来。我们在杜兴氏肌营养不良症（Duchenne）和肢带型肌营养不良症（LGMD）方面担任领导职务，并正在建立一套涵盖肌肉，中枢神经系统和心脏疾病的强大项目组合。

For more information, please visit .

有关更多信息，请访问。

www.sarepta.com

www.sarepta.com

or follow us on

LinkedIn

LinkedIn

,

,

X

十

,

,

Instagram

Instagram

and

和

Facebook

脸书

.

.

Internet Posting of Information

网上发布信息

We routinely post information that may be important to investors in the 'For Investors' section of our website at

我们经常在我们网站的“为投资者”部分发布对投资者可能重要的信息

www.sarepta.com

www.sarepta.com

. We encourage investors and potential investors to consult our website regularly for important information about us.

。我们鼓励投资者和潜在投资者定期咨询我们的网站，以获取有关我们的重要信息。

Forward Looking Statements:

前瞻性声明：

This press release contains “forward-looking statements.” Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements.

。诸如“相信”、“预期”、“计划”、“预期”、“将”、“可能”、“打算”、“准备”、“展望”、“潜力”、“可能”等词语以及类似的表达方式旨在识别前瞻性陈述。

These forward-looking statements include statements relating to our financial position, Sarepta 2030 goals and the revolving credit facility..

这些前瞻性报表包括与我们的财务状况、Sarepta 2030年目标和循环信贷安排有关的报表。。

These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our revenues and operating results could fluctuate significantly, which may adversely affect our stock price; if the actual number of patients suffering from the diseases we aim to treat is smaller than estimated, our revenue and ability to achieve profitability may be adversely affected; we may not be able to execute on our business plans, including meeting our expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing our product candidates to market, for various reasons, some of which may be outside of our control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates; and those risks identified under the heading “Risk Factors” in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review..

这些前瞻性陈述涉及风险和不确定性，其中许多超出了Sarepta的控制范围。由于此类风险和不确定性，实际结果可能与这些前瞻性声明所述或暗示的结果存在重大差异。已知的风险因素包括：我们的收入和经营业绩可能会大幅波动，这可能会对我们的股价产生不利影响；如果我们打算治疗的疾病的实际患者人数少于估计人数，我们的收入和盈利能力可能会受到不利影响；我们可能无法执行我们的业务计划，包括满足我们预期或计划的监管里程碑和时间表，研究和临床开发计划，以及将我们的候选产品推向市场，原因多种多样，其中一些可能超出我们的控制范围，包括公司财务和其他资源的可能限制，可能无法及时预期或解决的制造限制，以及监管，法院或机构的决定，例如美国专利和商标局关于涵盖我们候选产品的专利的决定；以及我们最近向美国证券交易委员会（SEC）提交的10-Q表季度报告中“风险因素”标题下确定的风险，以及鼓励您审查的该公司提交的其他SEC文件。。

Any of the foregoing risks could materially and adversely affect the Company’s business, results of operations and the trading price of Sarepta’s common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

上述任何风险都可能对公司的业务、经营业绩和Sarepta普通股的交易价格产生重大不利影响。有关萨雷普塔面临的风险和不确定性的详细描述，鼓励您查看萨雷普塔向美国证券交易委员会提交的文件。我们提醒投资者不要过分依赖本新闻稿中的前瞻性声明。

Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law..

除法律要求外，Sarepta不承担根据本协议日期后的事件或情况公开更新其前瞻性声明的任何义务。。

Source: Sarepta Therapeutics, Inc.

资料来源：Sarepta Therapeutics，Inc。